Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder.
暂无分享,去创建一个
Edward Kim | Chi-Chang Chen | S. Wisniewski | A. Pikalov | H. Kan | Edward Kim | Q. Tran | Stephen R Wisniewski | Zhenchao Guo | Zhenchao Guo | Chi-Chang Chen | Andrei Pikalov | Hong J Kan | Berit X Carlson | Quynh-Van Tran | B. Carlson
[1] R. Entsuah,et al. Global Benefit-risk Evaluation of Antidepressant Action: Comparison of Pooled Data for Venlafaxine, SSRIs, and Placebo , 2002, CNS Spectrums.
[2] C Chuang-Stein,et al. Three measures for simultaneously evaluating benefits and risks using categorical data from clinical trials. , 1991, Statistics in medicine.
[3] Aripiprazole augmentation for treatment of patients with inadequate antidepressants response , 2007, Depression and anxiety.
[4] R. Berman,et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. , 2007, The Journal of clinical psychiatry.
[5] M. Pollack,et al. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients , 2005, International clinical psychopharmacology.
[6] M. Fava,et al. Current Status of Augmentation and Combination Treatments for Major Depressive Disorder: A Literature Review and a Proposal for a Novel Approach to Improve Practice , 2006, Psychotherapy and Psychosomatics.
[7] Maurizio Fava,et al. Diagnosis and definition of treatment-resistant depression , 2003, Biological Psychiatry.
[8] P. Masand,et al. An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression. , 2006, Primary care companion to the Journal of clinical psychiatry.
[9] M. Fava,et al. The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Second Multicenter, Randomized, Double-Blind, Placebo-Controlled Study , 2008, Journal of clinical psychopharmacology.
[10] M. Fava,et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. , 2005, The Journal of clinical psychiatry.
[11] M. Fava,et al. Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies. , 2008, Primary care companion to the Journal of clinical psychiatry.
[12] C. Nemeroff,et al. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. , 2005, The Journal of clinical psychiatry.
[13] M. Thase,et al. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. , 2008, Journal of psychiatric research.
[14] D. Kupfer,et al. Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report , 2006 .
[15] R. Shelton,et al. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. , 2007, The Journal of clinical psychiatry.
[16] R. Tamura,et al. Global benefit–risk assessment in designing clinical trials and some statistical considerations of the method , 2008, Pharmaceutical statistics.
[17] Richard Entsuah,et al. Global benefit-risk assessment of antidepressants: venlafaxine XR and fluoxetine. , 2002, Journal of psychiatric research.